Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027

Nuvectis Pharma, Inc.

2024-FY EPS reported -$1.11

Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.
NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.
NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.
Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.
NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.